Marker Therapeutics, Inc.
MRKR
$0.88
-$0.04-3.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 861.20K | 349.10K | 2.25M | 1.93M | 1.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 861.20K | 349.10K | 2.25M | 1.93M | 1.17M |
| Cost of Revenue | 4.18M | 3.14M | 5.09M | 3.47M | 2.34M |
| Gross Profit | -3.32M | -2.79M | -2.83M | -1.55M | -1.17M |
| SG&A Expenses | 945.20K | 1.37M | 1.03M | 854.70K | 1.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.12M | 4.50M | 6.11M | 4.33M | 3.48M |
| Operating Income | -4.26M | -4.16M | -3.86M | -2.40M | -2.31M |
| Income Before Tax | -4.02M | -4.45M | -3.79M | -2.31M | -2.19M |
| Income Tax Expenses | -- | -- | 50.00K | -- | -- |
| Earnings from Continuing Operations | -4.02M | -4.45M | -3.84M | -2.31M | -2.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.02M | -4.45M | -3.84M | -2.31M | -2.19M |
| EBIT | -4.26M | -4.16M | -3.86M | -2.40M | -2.31M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.29 | -0.40 | -0.42 | -0.26 | -0.25 |
| Normalized Basic EPS | -0.18 | -0.22 | -0.26 | -0.16 | -0.15 |
| EPS Diluted | -0.29 | -0.40 | -0.42 | -0.26 | -0.25 |
| Normalized Diluted EPS | -0.18 | -0.22 | -0.26 | -0.16 | -0.15 |
| Average Basic Shares Outstanding | 13.96M | 11.11M | 9.18M | 8.92M | 8.92M |
| Average Diluted Shares Outstanding | 13.96M | 11.11M | 9.18M | 8.92M | 8.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |